Prescribing information and Adverse event reporting can be found at the bottom of the page

This website is intended for Great Britain healthcare professionals only

The current treatment landscape and the future for treating mCRC

The first in a series of podcasts hosted by experts in the field of mCRC. Hear Prof Tim Iveson discuss the current treatment options for patients with mCRC, as well as a look toward the future for treatment with Dr Sheela Rao.

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.


Professor Tim Iveson

Professor Tim Iveson

Prof Iveson has been a Consultant Medical Oncologist at Southampton University Hospitals NHS Foundation Trust since November 1995. Since 2020, Prof Iveson has been Professor of Gastro-Intestinal Oncology at Southampton University.


He qualified from St. Bartholomew’s Hospital in 1984 and undertook his Oncology training at the Royal Marsden Hospital.


He specialises in the treatment of Gastro-intestinal cancers and actively participate in local, national and international trials with over 90 publications in peer-reviewed journals and presentations at National and International conferences.


Prof Iveson was the Chief Investigator of the MRC SCOT and part of the IDEA collaboration. He is involved in patient information and was the Chief Medical Editor for Macmillan Cancer Support.

Dr Sheela Rao

Dr Sheela Rao

Dr Rao is a Consultant Medical Oncologist specialising in gastrointestinal cancers and cancers of unknown primary within the Gastrointestinal Unit at the Royal Marsden Hospital.


Dr Rao completed medical training at Charing Cross and Westminster Medical School and specialist oncology training at The Royal Marsden. She undertook laboratory-based research at The Institute of Cancer Research, supported by an academic grant, examining the prognostic and predictive value of genomic profiling of tumour biopsies in oesophago-gastric cancer.


Her main clinical interest is the sequencing of all modalities of treatment using the multidisciplinary team to achieve the best overall outcome for patients whilst aiming to improve or maintain quality of life and consider the patient’s wishes and ambitions.


She is The Royal Marsden's lead for cancers of unknown primary. Her research interests include clinical trials with novel therapies in GI cancers and she is the Principal investigator and Chief investigator on a number of national and international trials with novel agents and immunotherapy.


She serves on the committees for the UK National Cancer Research Institute (NCRI) Colorectal Cancer and Anal-Rectal Clinical Study Groups and is an active member of the International Rare Cancers Initiative (IRCI). She serves on the European Society of Medical Oncology (ESMO) educational faculty for GI Tumours. She sits on a number of national and international trial management groups and data monitoring committees.


Dr Rao is an active contributor to international research through peer-reviewed journals and conferences and has given invited lectures globally. She is a strong advocate for collaboration nationally and globally to improve research in GI cancers and works with a network of national and international colleagues to achieve this.

Want to stay in touch?

If you would like us to keep you up to date with details of future webinars and other important news updates, please stay connected using the button below.


Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email:


If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.